Article Text

Download PDFPDF

LSO-105 D-ALW nanoparticles ameliorate lupus nephritis in MRL/lpr mice
  1. Yaqi Wang,
  2. Huixia Wang and
  3. Yumin Xia
  1. Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, China


Background Anti-dsDNA antibody-targeting peptide mimic ALW has been reported to be a potential strategy in attenuating lupus-like disease in MRL/lpr mice. However, the therapeutic effect of peptide has been hampered due to its unstable architecture and non-renal targeting. Here, we describe a strategy of D-amino acid modified peptide and further engineered it by nanoparticle delivery system to overcome the obstacles in lupus nephritis therapy.

Methods The binding efficiency of D-form mimic peptide (D-ALW) to anti-dsDNA antibodies was assessed in vitro by surface plasma resonance and enzyme-linked immunosorbent assay (ELISA). The inhibition capacity of D-ALW affinity to autoantigens, mesangial cells and glomeruli was determined by inhibitory ELISA, flow cells, and glomerular binding assay. The proteolysis resistance of D-ALW was measured by high-performance liquid chromatography. The peptide D-ALW engineered by PEG-PLGA nanoparticles was injected into BALB/c mice to determine its attenuation in blood and biodistributions in tissue. Polyethylene glycol coated poly lactic-co-glycolic acid was used for the preparation of D-ALW nanoparticles, which were then administered to MRL/lpr mice. The serum anti-dsDNA IgG, complement 3 (C3), proteinuria, renal histopathologic, and renal IgG deposition were analyzed accordingly.

Results D-ALW, but not L-form ALW, can efficiently resist the proteolysis and possess a higher ability of binding to anti-dsDNA antibody IgG isotypes and blocking the binding of the anti-dsDNA antibody to multiple antigens, mesangial cells or glomeruli in vitro. In vivo studies showed that, compared to D-ALW, D-ALW nanoparticles with specific diameter and charge largely enhanced half-life in sera and accumulation in kidneys. D-ALW nanoparticles even improved the renal IgG deposition and glomerular fibrosis in MRL/lpr mice, accompanied by prolonged life-span.

Conclusions This study demonstrated that D-form ALW peptide possesses high efficiency and stability. D-ALW nanoparticles with special kidney-targeting ability can ameliorate the nephritis in MRL/lpr mice, possibly through inhibiting pathogenic renal IgG deposition and fibrosis.

  • ALW peptide
  • anti-dsDNA antibody
  • lupus nephritis

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.